https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812

As high-risk invasive medical devices directly penetrating human tissue, percutaneous breast biopsy instruments are subject to stringent legal statutes and standardized specifications governing safety and clinical performance. In China, the rollout and enforcement of industry standard YY/T 1929–2024 alongside progressively refined regulatory requirements have ushered the sector into a new era of rigorous compliance and high-quality development.

Full implementation of core industrial standard YY/T 1929–2024 marks a new milestone in industry standardization. Published by the National Medical Products Administration (NMPA) on February 7, 2024 and officially effective March 1, 2025, the specification was drafted under the lead of enterprises including Xishan Science & Technology. It systematically unifies terminology and definitions for breast biopsy and rotational excision devices as well as their matched rotary biopsy needles, and sets out definitive specifications covering raw materials, functional performance and corresponding test methodologies. The standard applies broadly to vacuum-assisted rotary excision systems and all associated biopsy needle consumables. A standout provision is the mandatory stiffness testing: by simulating biomechanical properties of human breast tissue, controlled compressive load is applied to quantify needle deformation, verifying sufficient bending and fracture resistance essential for intraoperative procedural safety. Furthermore, the standard stipulates concrete technical thresholds for critical parameters including cutter rotating speed/cutting frequency, vacuum pressure, sampling notch dimension, penetration performance, corrosion resistance and biological safety profiles.

Tougher, granular pre-market registration reviews have raised market access thresholds for such devices. The Guidelines for Registration Review of Breast Rotary Biopsy Needles and Accessories (Draft for Comments) issued by NMPA's Center for Medical Device Evaluation (CMDE) enforces full-lifecycle, refined regulatory requirements for these Class III medical devices. First, strict definition is mandated for intended use and product indication: devices must be designated for exclusive matching with specified rotary biopsy systems under image-guided percutaneous sampling, with standardized labeling prohibiting arbitrary expansion of clinical application scope. Second, tightened rules govern registration unit segmentation: products differing in core raw materials or compatible master units that lead to divergent performance criteria must file separate registration applications, substantially lifting registration costs and timeline for manufacturers with multi-specification product portfolios.

Non-clinical laboratory studies constitute the core and bottleneck of regulatory assessment. Updated codes require manufacturers to submit comprehensive, robust preclinical test dossiers. Full-life-cycle risk management is compulsory with focused mitigation targeting high-risk hazards such as cannula fracture, incomplete resection leading to residual lesions, specimen loss and mismatching between probes and host equipment. Product technical specifications have been greatly expanded: beyond routine metrics of dimensional tolerance, sterility and ethylene oxide (EO) residual limit, newly enforced mandatory items cover sampling recess length, internal lumen patency, connector tensile strength, specimen harvest weight, negative-pressure resistance of vacuum tubing, imaging visibility under clinical modalities, and MRI compatibility where applicable. Compatibility verification has been elevated to unprecedented priority; testing must replicate worst-case clinical operating conditions to validate seamless fit between biopsy needles, driving handpieces and main rotary units via physical measurement of cutting kinematics, maximum allowable sampling cycles and intact specimen yield.

Robust full-scale quality management systems underpin consistent product safety and efficacy. Starting from incoming raw material control, cannula stock such as medical stainless steel must comply with designated material standards accompanied by complete quality records and biocompatibility test reports in accordance with GB/T 16886.1. Fabrication is required to be performed within controlled cleanroom environments, with core processes including tip grinding and final assembly subject to stringent process validation and in-process quality surveillance. Sterilization validation must achieve a Sterility Assurance Level (SAL) of 10⁻⁶; products sterilized via ethylene oxide require full sterilization cycle validation and residual EO quantification testing. Real-time and accelerated aging stability trials determine labeled shelf life, supplemented by transit simulation testing to guarantee stable functional performance throughout the validated expiry period.

Evolving regulatory landscape bears far-reaching implications for industry participants. Enforcement of the latest standards and policies ends the previous loosely regulated filing era and shifts the breast biopsy device sector toward strict compliance and rigorous verification. Emerging domestic startups can no longer rely on abbreviated technical documentation or haphazard product variant grouping, and are obligated to allocate increased capital to rigorous R&D and preclinical validation. Foreign original equipment manufacturers must ensure models, structural design and product labeling filed for China registration fully align with original marketing approval documentation from their home jurisdictions, alongside stricter quality system audits and on-site factory inspections. While these reforms temporarily raise industrial entry barriers and production costs, they will in the long run drive overall quality upgrading of domestic products, standardize market competition and ultimately safeguard end-user medical device safety for patients.